It’s important to lay strong foundations for successful drug discovery at this first stage of the process. Our integrated target identification and validation platform combines AI with expert insights, and rigorous lab validation to guide targets through robust evaluation, ready for hit discovery.
Validated, high-quality hits, delivered through integrated technologies and expert collaboration, give you a confident starting point for faster drug discovery.
Turning promising leads into clinical candidates with speed, precision, and the scientific expertise to generate high-quality data and deliver real patient impact.
Delivering integrated, modality-agnostic drug discovery to tackle complex biology, accelerate development, and advance innovative therapies with confidence.
Advancing next-generation ADCs through payload-focused design, integrated expertise, and collaborative innovation to deliver safer, more selective therapies.
Driving biologics innovation through integrated design, structural biology, and multidisciplinary expertise to accelerate next-generation therapies from concept to clinic.
Combining deep therapeutic expertise with translational insight to design strategies, reduce risk, and accelerate discovery programs toward clinical success.
Accelerating oncology drug discovery through integrated expertise, innovative modalities, and translational insight to deliver candidates with real clinical impact.
Driving immunology and inflammation drug discovery through tailored assays, translational models, and integrated expertise for faster clinical success.
Advancing CNS drug discovery through integrated models, translational biomarkers, and multidisciplinary expertise to overcome complexity and accelerate therapeutic innovation.
Designing and advancing differentiated small-molecule therapies for obesity and diabetes through integrated expertise, mechanistic insight, and translational strategies.
Inobrodib, an exciting, first-in-class oral anti-cancer drug in clinical development by CellCentric, was collaboratively designed, synthesised and supported on its pre-clinical journey by an integrated project team at Sygnature Discovery. Inobrodib is now showing promising results in Phase I and II trials for multiple myeloma and other cancer types.
It’s important to lay strong foundations for successful drug discovery at this first stage of the process. Our integrated target identification and validation platform combines AI with expert insights, and rigorous lab validation to guide targets through robust evaluation, ready for hit discovery.
Validated, high-quality hits, delivered through integrated technologies and expert collaboration, give you a confident starting point for faster drug discovery.
Turning promising leads into clinical candidates with speed, precision, and the scientific expertise to generate high-quality data and deliver real patient impact.
Delivering integrated, modality-agnostic drug discovery to tackle complex biology, accelerate development, and advance innovative therapies with confidence.
Advancing next-generation ADCs through payload-focused design, integrated expertise, and collaborative innovation to deliver safer, more selective therapies.
Driving biologics innovation through integrated design, structural biology, and multidisciplinary expertise to accelerate next-generation therapies from concept to clinic.
Combining deep therapeutic expertise with translational insight to design strategies, reduce risk, and accelerate discovery programs toward clinical success.
Accelerating oncology drug discovery through integrated expertise, innovative modalities, and translational insight to deliver candidates with real clinical impact.
Driving immunology and inflammation drug discovery through tailored assays, translational models, and integrated expertise for faster clinical success.
Advancing CNS drug discovery through integrated models, translational biomarkers, and multidisciplinary expertise to overcome complexity and accelerate therapeutic innovation.
Designing and advancing differentiated small-molecule therapies for obesity and diabetes through integrated expertise, mechanistic insight, and translational strategies.
Inobrodib, an exciting, first-in-class oral anti-cancer drug in clinical development by CellCentric, was collaboratively designed, synthesised and supported on its pre-clinical journey by an integrated project team at Sygnature Discovery. Inobrodib is now showing promising results in Phase I and II trials for multiple myeloma and other cancer types.
Lipophilicity and solubility are more than numbers; they’re predictors of success. By combining advanced methodologies with expert interpretation, Sygnature Discovery helps you optimize drug design strategies, reduce risk, and move confidently toward clinical milestones.
Sygnature Discovery delivers comprehensive physicochemical assessments that guide early-stage drug design and preclinical development.
Our profiling capabilities focus on two essential parameters – lipophilicity and solubility – which directly influence absorption, distribution, and overall pharmacokinetic behavior. These insights help you inform decisions that reduce risk and accelerate progress through the discovery pipeline.
Lipophilicity Profiling
Lipophilicity plays a critical role in a drug’s pharmacokinetics, shaping absorption, tissue distribution, protein binding, and solubility. While higher lipophilicity can improve membrane permeability and bioavailability, excessive lipophilicity may reduce solubility and increase toxicity risks.
LogD
Miniaturized shake-flask method, quantifying Octanol: buffer partitioning at pH 7.4
A SFC-based approach that measures exposed polar surface area and internal hydrogen bonding. This predicts membrane permeability, particularly useful for beyond-Rule-of-5 molecules.
Solubility determines how well a compound performs in vitro and in vivo. Poor solubility can compromise assay reliability and limit absorption and bioavailability, ultimately affecting therapeutic exposure.
Kinetic Solubility (Turbidmetric)
Provides early-stage estimates to guide study design and interpret in vitro data.
Sygnature Discovery’s thermodynamic solubility validation confirms a robust, equilibrium‑based method for generating high‑confidence solubility data across pH 7.4 buffer and biorelevant media including FaSSIF, FeSSIF and FaSSGF. The assay demonstrates strong reproducibility, good agreement with literature values and clear compound‑dependent solubility shifts, supporting absorption prediction, medicinal chemistry optimisation and formulation strategy development.
Sygnature Discovery’s Turbidimetric Kinetic Solubility validation demonstrates a fast, high‑throughput method for determining aqueous solubility through turbidity measurements in physiological buffer. With consistent performance across controls and a broad set of test compounds, the assay reliably distinguishes high, moderate and low solubility ranges, supporting early decision‑making in in vitro discovery workflows.
Sygnature Discovery’s EPSA validation demonstrates a fast and reliable SFC‑MS method for estimating exposed polar surface area and understanding how effectively compounds can shield polarity. With optimised chromatography, consistent retention times and strong reproducibility, the assay supports rapid permeability assessment—especially valuable for bRo5 molecules and bifunctional degraders.
Sygnature Discovery’s ChromLogD validation demonstrates a fast and reliable chromatographic approach for determining lipophilicity, with excellent reproducibility across inter‑ and intra‑assay experiments. The method offers a practical, high‑throughput alternative to shake‑flask assays, supporting confident ADME decision‑making in early drug discovery.
Sygnature Discovery’s LogD7.4 validation confirms the assay’s accuracy and reproducibility across a wide range of compound lipophilicities. Using a classical shake‑flask approach with LC–MS/MS quantification, the method shows strong alignment with literature values and low variability across repeat assays, providing high‑quality lipophilicity data to support confident early‑stage ADME decision‑making.
We bring together a dynamic blend of new talent and experienced pharmaceutical industry experts from a round the world, delivering excellence across every stage of discovery.
Integrated solid form and formulation strategies reduce risk, improve stability and solubility, and accelerate progression from candidate selection to clinic.
Validated in vivo models deliver clinically relevant data across therapeutic areas, accelerating confident decisions and reducing risk in drug development.
